Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Aug;37(4):216-22.
doi: 10.4143/crt.2005.37.4.216. Epub 2005 Aug 31.

Thymidylate synthase, thymidine phosphorylase, VEGF and p53 protein expression in primary colorectal cancer for predicting response to 5-fluorouracil-based chemotherapy

Affiliations

Thymidylate synthase, thymidine phosphorylase, VEGF and p53 protein expression in primary colorectal cancer for predicting response to 5-fluorouracil-based chemotherapy

Myung-Ju Ahn et al. Cancer Res Treat. 2005 Aug.

Abstract

Purpose: In the treatment of advanced metastatic colorectal cancer, several new agents, such as irinotecan and oxaliplatin, have been developed, which have improved both disease free and overall survivals. Among these agents, 5-fluorouracil (5-FU) still remains one of the most active agents, and the selection of patients who can benefit from 5-FU-based chemotherapy is still important, as those unlikely to benefit could be spared the harmful side effects. The expression levels of thymidylate synthase (TS), thymidine phosphorylase (TP) and p53 have been known to be associated with the clinical response to 5-FU-based therapy as well as the prognosis, and that of vascular endothelial growth factor (VEGF) is associated with poor survival.

Materials and methods: The relationship between the expressions of TS, TP, VEGF and p53 in primary tumors, using immunohistochemistry, and the response of 45 metastatic colorectal cancer patients (M:F=25:20, median age 59 yrs) to 5-FU-based chemotherapy were evaluated.

Results: Thirty-seven patients were treated with 5-FU/LV/irinotecan (FOLFIRI) and 8 with 5-FU/LV/oxaplatin (FOLFOX). The overall response rate was 28.9% (13/45). When immunohistochemically analyzed with monoclonal antibodies against TS, TP, VEGF and p53, 55.6% of the patients (25/45) were positive for TS, 48.9% (22/45) for TP, 82.2% (37/45) for VEGF, and 80% (36/45) for p53. There was a significant difference in the intensity of TS expression between the clinical responders and non-responders (p=0.036). In terms of the staining pattern of TS expression, diffuse staining was correlated with a poor response (p=0.012) and poor survival (p=0.045). However, there was no correlation between the expressions of TP, VEGF or P53 and the response to chemotherapy.

Conclusion: These results suggest that the expression of TS in primary colorectal cancer might be an important prognostic factor for chemotherapy response and survival, and might be a useful therapeutic marker for the response of chemotherapy.

Keywords: Fluorouracil; Metastatic colorectal cancer; Thymidine phosphorylase; Thymidylate synthase; Vascular endothelial growth factor A; p53.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
A panel of immunohistochemical staining for TS (A), TP (B), p53 (C) and VEGF (D) in primary colorectal cancer (original magnification, ×200).
Fig. 2
Fig. 2
Overall survival according to the thymidylate synthase expression (A) overall survival according to intensity (B) overall survival according to staining pattern.

Similar articles

Cited by

References

    1. Johnston PG, Allegra CJ. Colorectal cancer biology: clinical implications. Semin Oncol. 1995;22:418–432. - PubMed
    1. Shin HR, Jung KW, Won YJ, Park JG KCCR-Affiliated Hospitals. 2002 Annual Report of the Korea Central Cancer Registry; Based on registered data from 139 hospitals. Cancer Res Treat. 2004;36:103–114. - PMC - PubMed
    1. Grem JL. Fluorinated pyrimidines. In: Chabner BA, Collins JM, editors. Cancer chemotherapy, principles and practice. Philadelphia, PA: Lippincott; 1990. pp. 180–224.
    1. Moertel CG. Chemotherapy for colorectal cancer. N Engl J Med. 1994;330:1136–1142. - PubMed
    1. Sotos GA, Grogan L, Allegra CJ. Preclinical and clinical aspects of biomodulation of 5-fluorouracil. Cancer Treat Rev. 1994;20:11–49. - PubMed